


# Not by Choice, But by Necessity: An Institutional Response to Research and the Pandemic

Clinical Trials Ontario

11 November 2022

Patrick Clifford BA, BSW, BEd, MSW, RSW

# In the Beginning



# As we Stabilized



1

Development and implementation of a phased organizational and service re-opening plan, consistent with PH, local and MoH /OH / OHA guidance



2

Began to re-engage ambulatory services and visits, prepare for increase in ambulatory visits



3

Aligning re-opening with organizational priorities, and only as necessary and consistently across organization, according to organizational priorities, monitor indicators (local trends, staffing, PPE, supply chain, PHO etc.)



4

Be prepared to reduce volume/activity at any point



5

Continue to offer alternative care delivery methods (video/phone/email)

# Dawn of the New Normal

Health care sector recognition that the horse is now well out of the barn (new service delivery / care delivery models/expectations) - No retreat




On the research front, adoption out of necessity of many of the elements of “Decentralized Clinical Trials” (DCTs) has occurred, not by choice but by necessity during the initial COVID era



Interface of long known consumer demand for more flexible health care delivery models, structures, process and recent lived experience with COVID has driven base state expectations – No retreat



Research specific impacts - Desire by patients/participants, industry and many PI's and teams along with HC and others to modernize the approach to trials found its burning platform. Strategic opportunity for change/evolution




# Moving Forward – Health Sector Realizations



- Digital and technological solutions have catapulted forward (Digitization is a model, not a technology construct)
  - A range of ambulatory services have and will move to virtual
  - Remote monitoring has and will continue to be propelled forward
  - Quality, data, platforms, security, privacy, identity, user experience, interoperability, AI/ML, business cases, national standards/regulation will be critical
- Moving ambulatory care and care not required in an acute care setting to the community must evolve
- Care at home - Home and community based care and mechanisms to support have been pushed forward by several years, Hospital at Home, Medical Home/Neighbourhood for more acute
- Care delivery models are changing, within and outside traditional institutions (preventative, acute, post-acute, chronic, end of life), social care
- Volume to Outcome / Quadruple Aim (pop health, patient experience, provider experience, cost)
- Primary Care reform more critical than ever, including expansion of potential providers (NP's, non-traditional, psychologists, pharmacists etc.), team based, infrastructure, reimbursement models, data systems
- Health Equity and the Social Determinants of Health have once again, this time more prominently been shown to matter
- The need for health care and public health preparedness
- Provider/patient relationships have and will continue to change
- Patient as consumer has an unrelenting momentum
- User experience is the new normal
- Low Rules environments must continue
- HHR / workforce planning, licensure rules must evolve
- Reimbursement models must mature > pay for outcomes

# DCTs to the Rescue



# Institutional Angst

1. Relationship of Research to Core business (community versus academic hospitals)
2. Staffing – employment, liability, insurance, performance, financial impacts, safety onsite/offsite/participants home (mobile HCPs as institution providers)
  1. Staffing – Mobile HCPs - contract/community staff, third party vendors, contracts, legal, licensure, union issues for home visits, training, oversight and liability
3. External Labs/Imaging and relationship to hospital/clinical care – secondary/incidental findings
  1. Clinical care/routine care vs. clinical trial activities – secondary findings, adverse events
4. DCT – 3<sup>rd</sup> party vendors, turn key services – impacts on current hospital based paradigm
5. Physician/Provider licensure/regulator/reimbursement (Reimbursement for digital/remote etc.)
6. Provincial / Federal legislative framework(s). Geographical jurisdictional issues, compliance with HC, FDA , HCP regulatory
7. CTA's, trial agreements, indemnity and insurance issues, reimbursement model, budgets, additional complexity/costs
8. Equity
9. IMP and role of hospital pharmacy, legislation, regulatory colleges, dispensing, in-house pharmacy or 3<sup>rd</sup> party pharmacy and delivery/accountability system
10. Governance and Risk Management
11. Changing norms/culture – playbooks, change management, best practices, changed operating models, pain points, impacts on cost/revenue models, traditional/hybrid/pure DCT, KPI's
12. Legal, Liability and Insurance (remote staff, in-home visits by staff/contractors, privacy/breaches), adverse events, process issues (eRecruitment, eConsent – understanding, identity validation)
13. IT/Privacy/Security
  1. Staff use of platforms/systems, digital/remote technologies (apps, wearables, RMT services), bandwidth, cloud, on-prem, system access/capabilities, remote (work from home) or participants home
  2. Use of AI/ML components
  3. Participants – access to, use of, support/training needs
  4. Storage of digital information, PHI, PI, PROMs Real World Data (RWD)
  5. Technologies – reliability, quality, security, privacy, use of pre-existing platform/technology versus adding new, existing/new 3<sup>rd</sup> party vendors, costs
  6. Data integrity/quality/interoperability, (RWD) interfaces with EMR, existing platforms/technology, data >verification, validation, usability
  7. Financial considerations related to IT/Privacy/Security, data integrity, additional storage costs, technology support/training
14. REB capability, expertise, span of control, alignment of organizational policies, Research SOPs, RHPA regulations, PHIPA, additional organizational burden
15. Safety Monitoring – lead / satellite site >accountabilities/responsibilities, legal, liability, insurance, quality, qualifications, monitoring, training
16. Traditional trials > DCTs, > In Silico trials (computational models to simulate how a drug, medical device, or intervention will affect a virtual population) (radiology/phantoms)



# Not by Choice, But by Necessity: An Institutional Response to Research and the Pandemic